Eli Lilly (LLY)

Skye Bioscience's latest data show nimacimab boosted tirzepatide's weight loss effects and reduced obesity treatment rebound risk.

The company's innovative engine continues to function well.

Consensus price targets set by experts who follow these businesses are way above their recent prices.

Viking aims to enter the billion-dollar weight loss drug market.

Eli Lilly's olomorasib with Merck's Keytruda receives FDA Breakthrough Therapy status for KRAS G12c lung cancer, supported by trial results.

Direxion MD Edward Egilinsky says traders are locking profits, hedging market highs, and using Palantir inverse ETFs for tactical moves.

Both companies have made significant progress in recent years.

There is something for everyone in this list of excellent stocks to buy.

The weight-loss drug opportunity could approach $100 billion by the end of the decade.

There are new ways to tackle weight loss, but the stocks leading the way are lagging.

Chinese suppliers of semaglutide and tirzepatide that fueled a U.S. weight-loss drug boom are pivoting to generics as FDA crackdowns.

A 57% risk reduction for heart attacks and strokes sounds like an amazing result.

The specter of persistent inflation continues to loom large over the U.S. economy, keeping both consumers and policymakers on edge. Despite the Federal Reserve's aggressive campaign of interest rate hikes, the Personal Consumption Expenditures (PCE) price index, the central bank's preferred gauge of inflation, continues to run above its

Each trading day features hundreds of headlines and press releases on Benzinga Pro, a source for traders to see the latest news on the overall market and individual tickers.

Novo Nordisk's Wegovy cut cardiovascular risks significantly versus tirzepatide in a real-world study, showing fewer heart attacks, strokes, and deaths.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Elanco (NYSE:ELAN) and the best and worst performers in the pharmaceuticals industry.

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

This could put pressure on Eli Lilly, which sells a competing drug called Kisunla.

A significant sector rotation is currently underway in equity markets, shifting investor capital away from the mega-cap technology stocks that dominated recent years towards more traditional value and cyclical segments. This trend, gaining significant momentum in 2025, sees sectors such as financial services, basic materials, healthcare, energy, and industrials outperforming,

Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.

The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.

Here's why investors aren't sure what to make of Nvidia earnings.